Observing the effects of ropeginterferon alfa-2b in patients with Polycythemia Vera

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the use of ropeginterferon alfa-2b in patients diagnosed with Polycythemia Vera (PV). It will assess how well the drug can be prescribed and tolerated in real-world clinical settings, focusing on the risk-benefit profile of the treatment. The study will include patients who require cytoreductive treatment and will follow them over time to gather data on the drug's effectiveness and safety. The findings will help inform clinical practice for managing PV.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients diagnosed with Polycythemia Vera by WHO 2016
* Patient aged ≥ 18 years old
* Patients in need of cytoreductive treatments with ropeginterferon alfa-2b in first or later lines according to the reimbursability criteria defined by the Italian National Health System
* Patients who have signed the written informed consent for study participation.

Exclusion Criteria:

• Any contraindication for ropeginterferon alfa-2b according to the SmPC

Where it's running

• SC Ematologia, ASST Papa Giovanni XXIII
  Bergamo, Lombardy, Italy Recruiting
• Divisione Ematologia ASST, Grande Ospedale Metropolitano Niguarda
  Milan, Lombardy, Italy Recruiting
• Divisione Ematologia, Fondazione IRCCS Policlinico San Matteo
  Pavia, Lombardy, Italy Recruiting
• U.O. Ematologia, Ospedale di Circolo e Fondazione Macchi Varese
  Varese, Lombardy, Italy Recruiting
• Clinica Medica I Azienda Ospedaliera di Padova
  Padova, Veneto, Italy Recruiting
• Divisione Ematologia, Ospedale Borgo Roma
  Verona, Veneto, Italy Recruiting

Study contacts

• Study coordinator: Tiziano Barbui, Md
• Email: tbarbui@fondazionefrom.it
• Phone: +39 0352675134

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MPNdpoint: Long-term Look at Philadelphia-negative Myeloproliferative Neoplasms

  This study tests how outcomes differ for patients 16 and older with polycythemia vera, essential thrombocythemia, or myelofibrosis by collecting and analyzing clinical and treatment data.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07863466

• Test of bomedemstat for polycythemia vera in adults

  This study tests bomedemstat (MK-3543) to see if it helps people with polycythemia vera reach healthier blood counts compared with standard treatments.

  Recruiting at 5 sites Phase 2/3 Merck Sharp & Dohme LLC · Newark, Delaware and 4 other locations · NCT07722611

• Rusfertide in Japanese adults with polycythemia vera

  This study tests rusfertide in Japanese adults with polycythemia vera to see if it helps keep hematocrit under control and reduce the need for blood removal.

  Recruiting at 8 sites Phase 2 Takeda · Nagoya, Aichi-ken and 8 other locations · NCT07648030

• Sapablursen added to standard care for people with polycythemia vera

  This trial will test whether adding sapablursen to standard therapy can reduce the need for phlebotomy in people with polycythemia vera who remain phlebotomy-dependent.

  Recruiting at 38 sites Phase 3 Ono Pharmaceutical Co., Ltd. · Orange, California and 37 other locations · NCT07429266

• MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs.

  Track long-term symptoms, treatments, and disease progression in adults with myeloproliferative neoplasms to see how these conditions evolve over time.

  Recruiting at 2 sites MPN Research Foundation · Chicago, Illinois and 1 other locations · NCT07362225

• ELN multicenter analysis of phenotypic evolution and clinical outcomes

  This study tries to find features linked to JAK2V617F-positive essential thrombocythemia (ET) patients who later developed polycythemia vera (PV) by comparing them with matched ET patients who did not progress and with patients diagnosed with de novo PV.

  Recruiting at 10 sites FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS · Rochester, Minnesota and 23 other locations · NCT07203768

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.